IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff?

• The selloff follows the company's presentation of updated early-stage data for its pancreatic cancer drug, atebimetinib, at the ASCO 2026 Annual Meeting.
• The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients.
• Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.

Shares of Immuneering Corporation (IMRX) fell sharply on Monday, dropping about 23%, after the company presented updated early-stage data for its pancreatic cancer drug atebimetinib at the ASCO 2026 Annual Meeting.

Despite the positive results, the stock slipped following a recent run-up in the stock. The stock closed up 14% on the last trading day but is now on track to record its worst day since early January, if losses hold.

IMRX’s Trial Data

The new data showed a median overall survival of 17.3 months in first-line metastatic pancreatic cancer patients. That is more than double the 8.5-month historical average for the standard chemotherapy alone. Median progression-free survival was 8.3 months, with an objective response rate of 36% and a disease control rate of 82%. The drug was generally well tolerated, with no major new safety issues reported.

Both overall survival and median progression-free survival help doctors understand how well a cancer treatment is working. Overall survival (OS) is the length of time from the start of treatment until a patient dies from any cause, while median progression-free survival (PFS) measures the time from the start of treatment until the cancer worsens or the patient dies.

Immuneering is now moving the drug into a larger randomized Phase 3 trial, which is expected to begin dosing patients in mid-2026.

CEO Ben Zeskind said the results strengthen the company’s belief that atebimetinib could meaningfully improve outcomes for pancreatic cancer patients.

How Did IMRX Retail Traders React?

On Stocktwits, retail sentiment around IMRX stock rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.

A Stocktwits user attributed the stock drop to a “sell the news” event.

Another user cheered the “good results” and expressed optimism for the stock touching $6/ share this month.

According to data from Koyfin, all six analysts covering IMRX rate it ‘Buy’ or higher. The average 12-month price target on the stock is $17, representing a potential upside of about 195% from last closing price.

IMRX stock has gained over 138% over the past 12 months. 

Read More: RIVN Stock Surges For 8th Straight Day: Rivian’s Rival To Tesla Model Y Nears June 9 Delivery Kickoff

For updates and corrections, email newsroom[at]stocktwits[dot]com.